Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs TORM plc (TRMD) Price & Performance

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs TORM plc — how do they compare? Novo Nordisk A/S trades at $46.28 (market cap $207.85B), while TORM plc trades at $28.93 (market cap $2.93B). The key difference: Novo Nordisk A/S is far larger — about 70.9× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.

NVOTRMD
Market Cap
$207.85B$2.93B
Sector
HealthTechnology
52-Week High
$63.98$34.87
52-Week Low
$35.29$18.77
Enterprise Value
$222.55B$3.82B
Dividend Yield
3.81%9.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

TORM plc

TRMD trades at $28.84, down 1.2% with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $1.34B revenue, $285.3M net income, and a 24.41% net margin. Recent earnings show mixed performance with Q2 2026 expectations at $3.41 EPS. Analyst consensus remains unanimously bullish with 3 buy ratings. Technical indicators show oversold conditions with RSI at 24.63, while support levels cluster around $28.

The stock presents a value opportunity with attractive valuation multiples (P/E 8.4, EV/EBITDA 5.95) and strong profitability metrics (ROE 15.62%). Near-term catalysts include Q2 2026 earnings and the $0.70 dividend payment in June. Key risks include earnings volatility, tanker market cyclicality, and negative cash flow trends. Institutional ownership stability and positive analyst coverage support the bullish case despite technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About TORM plc

TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.

Read more on TRMD